Relationships of cytokine (GM-CSF) serum concentration to blood cell count and the inflammatory parameters in children with malignant diseases

Pediatric Hematology and Oncology

Volumn 16, Issue 6, 1999, Pages 509-518

  Müller, Cornelia E ^a   Mukodzi, S ^a   Reddemann, H ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Exogenous and endogenous concentration; GM CSF; Malignancy; Neutropenia

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ARTICLE; CANCER CHEMOTHERAPY; CELL COUNT; CHILD; DOSE RESPONSE; HUMAN; INFLAMMATORY CELL; MALIGNANT NEOPLASTIC DISEASE; MYELOPOIESIS; NEUTROPHIL; STEM CELL;

ACUTE-PHASE PROTEINS; ADOLESCENT; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; CHILD; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HUMANS; INFLAMMATION; KIDNEY FUNCTION TESTS; LIVER FUNCTION TESTS; MALE; NEUTROPENIA; NEUTROPHILS;

EID: 0344172564     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/088800199276796     Document Type: Article

References (15)

1. Marty, M (ed). Manual of GM-CSF. Oxford, UK: Blackwell Sciences; 1996.
2. Lau AS, Lehmann D, Geertsma FR, Yeung MC. Biology and therapeutic uses of myeloid hematopoietic growth factors and interferons. Pediatr Infect Dis J. 1996;15:563-575.
3. Furman WL, Crist WM. Potential uses of recombinant human granulocyte-macrophage colony stimulating factor in children. Am J Pediatr Hematol Oncol. 1991;13:388-399.
4. Furman WL, Fairclough DL, Huhn RD, et al. Therapeutic effects and pharmacokinetics of recombinant granulocyte-macrophage colony-stimulating factor in childhood cancel patients receiving myelosuppressive chemotherapy. J Clin Oncol. 1991;9:1022-1028.
5. Furman WL, Fairclough DL, Cain AM, Arnold BA, Meyer WH, Grist WM. Use of GM-CSF in children after high-dose chemotherapy. Med Pediatr Oncol Suppl. 1992;2:26-30.
6. Riikonen P, Saarinen UM, Mäkipernaa A, et al. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatr Infect Dis J. 1994;13:197-202.
7. Schrezenmeier H, Raghavachar A, Heimpel H. Granulocyte-macrophage colony-stimulating factor in the sera of patients with aplastic anemia. Clin Invest. 1993;71:102-108.
8. Suite N, Santana VM, Rodman JH, Scheel MJ, Ihle JN, Evans WE. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood. 1992;79:2849-2854.
9. Stute N, Furman WL, Schell M, Evans WE. Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration. J Pharm Sci. 1995;84:824-828.
10. Ragnhammar P, Friesen HJ, Frödin JE, et al. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in non-immunocompromised patients. Blood. 1994;84:4078-4087.
11. Schmidt W, Maass G, Buschle M, et al. Generation of effective cancer vaccines genetically engineered to secrete cytokines using adenovirus-enhanced transferinfection (AVET). Gene. 1997;190:211-216.
12. Yu JS, Burwick JA, Dranoff G, Breakefield XO. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther. 1997;8:1065-1072.
13. Dow SW, Elmslie RE, Willson AP, Roche L, Gorman C, Potter TA. In vivo tumor transfection with super-antigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest. 1998;101:2406-2414.
14. Heil G, Chadid L, Hoelzer D. GM-CSF in the therapy of de-novo AML patients: an update of a double-blind randomized, placebo controlled trial. Ann Hematol. 1995;70(Suppl. 2):A133.
15. Takahashi M, Nikkuni K, Moriyama A, Shibata A. GM-CSF-mediated impairment of liver to synthesize albumin, cholinesterase and cholesterol. Am J Hematol. 1991;36:213-214.